Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy

University of Sao Paulo30 enrolled

Overview

The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation. Two groups of patients were followed and the effect of the treatment (diclofenac plus laser) was compared to placebo (placebo plus laser). Pain associated with treatment was recorded using a Visual Analog Scale 15 minutes after the procedure.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Pain

Interventions

potassium diclofenacDRUG

potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1)high-risk proliferative diabetic retinopathy in both eyes Exclusion Criteria: * 1)history of prior laser treatment or vitrectomy; 2) allergy to non-steroidal anti-inflammatory drugs; 3) any condition affecting comprehension of VAS pain score test; 4) Contra-indications for diclofenac use such as pregnancy, bleeding disorders, asthma, or renal failure; 5) use of any analgesic drug for the last 24 hours.

Locations (1)

Ribeirão Preto School of Medicine Clinics Hospital - USP

Ribeirão Preto, São Paulo, Brazil

Outcomes

Primary Outcomes

Pain recorded using a Visual Analog Scale

Time frame: 15 minutes after the procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.